Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2014 | Pages:
313 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Merck & Co., Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Merck & Co., Inc. - Product Pipeline Review - 2014', provides an overview of the Merck & Co., Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Merck & Co., Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Merck & Co., Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Merck & Co., Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Merck & Co., Inc.'s pipeline products Reasons to buy - Evaluate Merck & Co., Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Merck & Co., Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Merck & Co., Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Merck & Co., Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Merck & Co., Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Merck & Co., Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Merck & Co., Inc. Snapshot 7 Merck & Co., Inc. Overview 7 Key Information 7 Key Facts 7 Merck & Co., Inc. - Research and Development Overview 8 Key Therapeutic Areas 8 Merck & Co., Inc. - Pipeline Review 18 Pipeline Products by Stage of Development 18 Pipeline Products - Monotherapy 19 Pipeline Products - Combination Treatment Modalities 20 Pipeline Products - Partnered Products 21 Pipeline Products - Out-Licensed Products 24 Merck & Co., Inc. - Pipeline Products Glance 27 Merck & Co., Inc. - Late Stage Pipeline Products 27 Merck & Co., Inc. - Clinical Stage Pipeline Products 31 Merck & Co., Inc. - Early Stage Pipeline Products 36 Merck & Co., Inc. - Drug Profiles 39 corifollitropin alfa 39 diquafosol tetrasodium 41 pembrolizumab 43 posaconazole 45 short ragweed pollen allergen OD 46 suvorexant 48 V-503 50 vaniprevir 52 vorapaxar sulfate 54 (formoterol fumarate + mometasone furoate) 56 ridaforolimus 58 sugammadex sodium 62 vintafolide 63 (actoxumab + bezlotoxumab) 66 (ertugliflozin + metformin) 67 (ertugliflozin + sitagliptin) 68 (etoricoxib + tizanidine) 69 (grazoprevir + elbasvir) 70 (losartan potassium + hydrochlorothiazide [INN] + amlodipine besylate) 72 anacetrapib 73 asenapine maleate 75 bezlotoxumab 76 desloratadine 77 elbasvir 78 grazoprevir 79 insulin glargine biosimilar 81 letermovir 83 MK-8237 84 MK-8931 86 odanacatib 87 omarigliptin 89 tildrakizumab 91 V-212 92 vorinostat 94 narlaprevir 97 BQ-123 98 dalotuzumab 100 doravirine 103 etonogestrel Vaginal Ring 104 lonafarnib 105 mirtazapine 107 MK-1029 108 MK-2206 109 MK-2206 + selumetinib sulfate 112 MK-4618 114 MK-7622 115 MK-7655 116 temozolomide 118 ubrogepant 120 V-114 121 MK-0752 122 CMX-157 124 MK-2248 125 MK-2748 126 MK-4074 127 MK-4166 128 MK-7145 129 MK-8150 130 MK-8226 131 MK-8242 132 MK-8351 134 MK-8353 135 MK-8408 136 MK-8521 137 MK-8655 138 MK-8666 139 MK-8723 140 MK-8876 141 MK-8892 142 Monoclonal Antibody for Autoimmune Diseases 143 rituximab biosimilar 144 SCH-772984 145 Small Molecule 1 for Human Cytomegalovirus Infection 146 Small Molecule 2 for Human Cytomegalovirus Infection 147 V-160 148 V-180 149 1D05-Fab 150 AM-251 151 Bio-Cojugates for Undisclosed Indication 152 DORA-12 153 Drug to Inhibit 11Beta-HSD1 for Hypertension 154 Drugs to Inhibit CYP11B2 for Cardiovascular Diseases 155 ETP-142 156 M-867 157 mDX-400 158 MK-8745 159 MK-8825 160 MRK-003 161 SCH-412348 162 SCH-546738 163 siRNA to Inhibit Angiotensinogen for Hypertension 164 Small Molecule 3 for Human Cytomegalovirus Infection 165 Small Molecule to Agonize Glucocorticoid Receptor for Respiratory Disorders 166 Small Molecule to Inhibit Glucagon Receptor for Diabetes 167 Small Molecule to Inhibit JAK2 for Myeloproliferative Disorder 168 Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease 169 Small Molecules to Inhibit Cav2.2 Channel for Chronic Pain 170 Spirohydantoins to Inhibit Prolyl Hydroxylase for Anemia 171 THPP-1 to Inhibit PDE10 for Schizophrenia and Cognitive Impairment 172 TROX-1 173 Vaccine for Chikungunya 174 Vaccine for Respiratory Syncytial Virus Infections 175 XEN-445 177 XL-499 178 Biosimilars for Undisclosed Indication 179 Hepatitis C Vaccine 180 Kibdelomycin A 181 Monoclonal Antibody for Cancer 182 Monoclonal Antibody for Neurology 183 SCH-722984 184 Small Molecules for Cardiovascular Disease 185 Small Molecules for Undisclosed Indication 186 Small Molecules to Agonize M1 for Alzheimer's Disease 187 Small Molecules to Inhibit Aspartyl Protease 189 Small Molecules to Inhibit CGRP Receptor for Migraine 190 Small Molecules to Inhibit DGAT1 for Undisclosed Indication 191 Merck & Co., Inc. - Pipeline Analysis 192 Merck & Co., Inc. - Pipeline Products by Target 192 Merck & Co., Inc. - Pipeline Products by Route of Administration 198 Merck & Co., Inc. - Pipeline Products by Molecule Type 200 Merck & Co., Inc. - Pipeline Products by Mechanism of Action 202 Merck & Co., Inc. - Recent Pipeline Updates 208 Merck & Co., Inc. - Dormant Projects 245 Merck & Co., Inc. - Discontinued Pipeline Products 260 Discontinued Pipeline Product Profiles 261 Merck & Co., Inc. - Company Statement 271 Merck & Co., Inc. - Locations And Subsidiaries 274 Head Office 274 Other Locations & Subsidiaries 274 Appendix 303 Methodology 303 Coverage 303 Secondary Research 303 Primary Research 303 Expert Panel Validation 303 Contact Us 304 Disclaimer 304
List of Tables Merck & Co., Inc., Key Information 16 Merck & Co., Inc., Key Facts 16 Merck & Co., Inc. - Pipeline by Indication, 2014 19 Merck & Co., Inc. - Pipeline by Stage of Development, 2014 27 Merck & Co., Inc. - Monotherapy Products in Pipeline, 2014 28 Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, 2014 29 Merck & Co., Inc. - Partnered Products in Pipeline, 2014 30 Merck & Co., Inc. - Partnered Products/ Combination Treatment Modalities, 2014 31 Merck & Co., Inc. - Out-Licensed Products in Pipeline, 2014 33 Merck & Co., Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 34 Merck & Co., Inc. - Pre-Registration, 2014 36 Merck & Co., Inc. - Filing rejected/Withdrawn, 2014 37 Merck & Co., Inc. - Phase III, 2014 38 Merck & Co., Inc. - Phase II, 2014 40 Merck & Co., Inc. - Phase I, 2014 42 Merck & Co., Inc. - Preclinical, 2014 45 Merck & Co., Inc. - Discovery, 2014 47 Merck & Co., Inc. - Pipeline by Target, 2014 202 Merck & Co., Inc. - Pipeline by Route of Administration, 2014 208 Merck & Co., Inc. - Pipeline by Molecule Type, 2014 210 Merck & Co., Inc. - Pipeline Products by Mechanism of Action, 2014 211 Merck & Co., Inc. - Recent Pipeline Updates, 2014 217 Merck & Co., Inc. - Dormant Developmental Projects,2014 254 Merck & Co., Inc. - Discontinued Pipeline Products, 2014 269 Merck & Co., Inc., Subsidiaries 283
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
